Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation
Articolo
Data di Pubblicazione:
2005
Citazione:
Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation / H. Holdaas, A. Corsini. - In: RENAL FAILURE. - ISSN 0886-022X. - 27:3(2005), pp. 259-273.
Abstract:
Premature atherosclerotic coronary heart disease driven by multiple risk factors is a major cause of morbidity and mortality among the 6 million patients in the United States with chronic renal failure. Consensus is that kidney failure and renal transplantation patients should be treated aggressively for dyslipidemia. Major medical literature databases were searched for published information about fluvastatin, a HMG-CoA reductase inhibitor, used in patients with impaired renal function. This article characterizes the dyslipidemia observed in these clinical settings and reviews the clinical experience with fluvastatin. Copyright (copyright) 2005 Taylor & Francis Inc.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
United States; chronic kidney failure; clinical trial; coronary artery atherosclerosis; data base; drug information; dyslipidemia; eye disease; gastrointestinal symptom; human; insomnia; kidney disease; kidney transplantation; liver disease; malignant neoplastic disease; medical literature; morbidity; mortality; myalgia; myopathy; nausea; priority journal; publication; review; rhabdomyolysis; risk factor; side effect; stomach disease; vomiting; atorvastatin; cyclosporin; fluindostatin; hydroxymethylglutaryl coenzyme A reductase inhibitor; mevinolin; placebo; pravastatin; rosuvastatin; simvastatin
Elenco autori:
H. Holdaas, A. Corsini
Link alla scheda completa: